Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13169643 | 0.80 | MAPT (0.33) | ATMSMN1; SMN2KDM4EMAPTHTT | |
| SCHEMBL13169646 | 0.77 | HRH3 (0.32) | ATMSMN1; SMN2KDM4EMAPTHTT | |
| SCHEMBL24978114 | 0.76 | HRH3 (0.36) | ATMMAPTHTT | |
| SCHEMBL13169644 | 0.67 | MAPT (0.33) | KDM4EGAAMAPTNLRP3 | |
| SCHEMBL21962199 | 0.63 | ATM (0.38) | ATMSMN1; SMN2KDM4ELMNAGAA | |
| SCHEMBL73966 | 0.63 | TSHR (0.39) | SMN1; SMN2KDM4EMAPT | |
| SCHEMBL13169652 | 0.63 | PTPN1 (0.32) | KDM4EGAA | |
| SCHEMBL25024717 | 0.63 | MAPT (0.55) | ATMSMN1; SMN2KDM4ELMNAGAA | |
| SCHEMBL22002673 | 0.63 | NLRP3 (0.41) | ATMSMN1; SMN2KDM4ELMNAGAA | |
| SCHEMBL7278399 | 0.62 | MAOA (0.42) | SMN1; SMN2LMNAMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-02 | — | — | US | disclosed |
| WO-2020102096-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | ATM 3677/4885SMN1; SMN2 2608/4885KDM4E 4525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.